Skip to main content

Research Repository

Advanced Search

All Outputs (5)

Effects of 1H-1,2,3-Triazole Derivatives of 3-O-Acetyl-11-Keto-Beta-Boswellic Acid from Boswellia sacra Resin on T-Cell Proliferation and Activation (2024)
Journal Article
Meyiah, A., Avula, S. K., Al-Harrasi, A., & Elkord, E. (in press). Effects of 1H-1,2,3-Triazole Derivatives of 3-O-Acetyl-11-Keto-Beta-Boswellic Acid from Boswellia sacra Resin on T-Cell Proliferation and Activation. Pharmaceuticals, 17(12), 1650. https://doi.org/10.3390/ph17121650

Background: 3-O-acetyl-11-keto-β-boswellic acid (β-AKBA), a triterpene natural product, is one of the main natural products of Boswellia sacra resin (BSR) and has reported biological and immunomodulatory effects. 1H-1,2,3-triazole derivatives of β-AK... Read More about Effects of 1H-1,2,3-Triazole Derivatives of 3-O-Acetyl-11-Keto-Beta-Boswellic Acid from Boswellia sacra Resin on T-Cell Proliferation and Activation.

Lymphocyte-activation gene 3 in cancer immunotherapy: function, prognostic biomarker and therapeutic potentials (2024)
Journal Article
Ren, K., Hamdy, H., Meyiah, A., & Elkord, E. (in press). Lymphocyte-activation gene 3 in cancer immunotherapy: function, prognostic biomarker and therapeutic potentials. Frontiers in Immunology, 15, 1501613. https://doi.org/10.3389/fimmu.2024.1501613

Lymphocyte-activation gene 3 (LAG-3) has emerged as a key immune checkpoint regulating immune responses in the context of cancer. The inhibitory effect of LAG-3-expressing T cells contributes to suppressing anti-tumor immunity and promoting tumor pro... Read More about Lymphocyte-activation gene 3 in cancer immunotherapy: function, prognostic biomarker and therapeutic potentials.

Turning Cancer Immunotherapy to the Emerging Immune Checkpoint TIGIT: Will This Break Through the Limitations of the Legacy Approach? (2024)
Journal Article
Tripp, R. A., Cui, H., & Elkord, E. (2024). Turning Cancer Immunotherapy to the Emerging Immune Checkpoint TIGIT: Will This Break Through the Limitations of the Legacy Approach?. Vaccines, 12(12), 1306. https://doi.org/10.3390/vaccines12121306

The discovery of immune checkpoints (ICs) has pushed cancer treatment into the next era. As an emerging immune checkpoint, the TIGIT/CD155 axis inhibits the cytotoxicity of T and NK cells through multiple pathways. Immune checkpoint inhibitors (ICIs)... Read More about Turning Cancer Immunotherapy to the Emerging Immune Checkpoint TIGIT: Will This Break Through the Limitations of the Legacy Approach?.

What is the relevance of FoxP3 in the tumor microenvironment and cancer outcomes? (2024)
Journal Article
Meyiah, A., & Elkord, E. (in press). What is the relevance of FoxP3 in the tumor microenvironment and cancer outcomes?. Expert Review of Clinical Immunology, 1-7. https://doi.org/10.1080/1744666X.2024.2334258

Forkhead box P3 (FoxP3) transcription factor plays critical roles in controlling immune responses and cancer progression in different cancers. FoxP3 expression within the tumor microenvironment (TME) may influence clinical outcomes negatively or posi... Read More about What is the relevance of FoxP3 in the tumor microenvironment and cancer outcomes?.